M&A activity in the pharmaceutical industry in Germany increased in 2023

In value terms, M&A activity in Germany remained flat in Q2 2023 compared with the previous quarter and as compared to Q2 2022. Related deal volume increased by 71% in Q2 2023 versus the previous quarter and was 140% higher than in Q2 2022.

The top-ranked legal advisorss supporting these M&A deals in Germany Q2 2023 were CMS Legal Services EEIG; Gleiss Lutz Hootz Hirsch; Heuking Kuhn Luer Wojtek with 1, 1, 1 deals respectively.

For further understanding of GlobalData’s Pharma Industry Mergers and Acquisitions Deals by Top Themes, buy the report here.

This content was updated on 18 July 2023

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Deals Database tracks global deal activity, including mergers, acquisitions, capital raising, strategic alliances, and licensing agreements. Proprietary analysis is used to group deals into key thematic areas and granular sectors across the world’s largest industries.

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Deal type includes Acquisition, Asset transactions and Mergers.

New Clues to Origin of T-Cell Lymphoma After CAR-T Therapy

Only one of 724 patients treated with chimeric antigen receptor (CAR) T-cell therapy for B-cell lymphoma subsequently developed a T-cell lymphoma, according to a large

June 13, 2024

‘Put him in jail.’ Steward CEO de la Torre skips hearing, now Congress is poised to hold him in contempt

Lawmakers in Washington turned their focus to the Steward Health Care bankruptcy scandal on Thursday, even as patients, doctors, and regulators across eight states continue

September 12, 2024

Data Insights – Pharmaceutical Technology

By Company Name No Filter Selected Bristol-Myers Squibb (346) Merck (243) Novartis (232) AstraZeneca (220) Pfizer (217) F. Hoffmann-La Roche (169) AbbVie (150) BeiGene (144)

March 14, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.